key: cord-0724963-83w43gcx
authors: Xiang, J.; Katz, L.; Winokur, P. L.; Chaudhary, A.; Bradford, R.; Rashid, S.; Ghosh, S.; Robertson, A.; Menetski, J.; Lee, T.; Poelaert, B.; Eastman, R. T.; Hall, M. D.; Stapleton, J. T.
title: Establishment of human post-vaccination SARS-CoV-2 standard reference sera
date: 2022-01-25
journal: nan
DOI: 10.1101/2022.01.24.22269773
sha: a9e50bcd24495372ac7116555257e8adcbd81fe8
doc_id: 724963
cord_uid: 83w43gcx

As SARS-CoV-2 variants emerge, there is a critical need to understand the effectiveness of serum elicited by different SARS-CoV-2 vaccines. A reference reagent comprised of post-vaccination sera from recipients of different vaccines allows evaluation of in vitro variant neutralization, and provides a reference for comparing assay results across laboratories. We prepared and pooled >1 L serum from donors who received the SARS-CoV-2 mRNA vaccines (BNT162b2, Pfizer and mRNA-1273, Moderna), a replication-incompetent adenovirus type 26 vaccine (Ad26.COV2.S, Johnson and Johnson), or recombinant spike protein expressed by baculovirus incorporated into a nanoparticle vaccine plus Matrix-M adjuvant (NVX-CoV2373, Novavax). Twice frozen sera were aliquoted and are available for distribution to the research community (BEI Resources). The calculated WHO titer of pooled sera to spike protein was 1,312, 1,447, 1,936, and 587 and the reciprocal RBD binding to ACE-2 IC90-titers were 60, 64, 118, and 46 for BNT162b2, mRNA1273, Ad26.CoV2373, and NVX-CoV2373 sera, respectively.

The calculated WHO titer of pooled sera to spike protein was 1,312, 1,447, 1,936, and 587 and the reciprocal RBD binding to ACE-2 IC90-titers were 60, 64, 118, and 46 for BNT162b2, mRNA1273, Ad26.CoV2373, and NVX-CoV2373 sera, respectively.

for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.24.22269773 doi: medRxiv preprint

RNA viruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have error-prone polymerases that result in high rates of genome mutation (1, 2) . This results in progeny virus genomes that differ from their parental templates, leading to the generation of viral quasispecies within and between individuals (3) . SARS-CoV-2 has evolved into variants of concern (VOC) that demonstrate mutations, including the gene that encodes the spike protein that mediates viral entry. These mutations may lead to enhanced transmissibility and new waves of infections (4), as seen most recently Delta (B.1.617.2 and sub-lineages) and Omicron (B.1.1.529) VOC (5, 6).

Among VOC, a critical issue is their potential for altered pathogenicity and immune escape from naturally occurring or vaccine-induced antibodies (7) .

As new SARS-CoV-2 variants emerge, there is an urgent need to understand the relative effectiveness of antibodies elicited by different SARS-CoV-2 vaccines to neutralize VOC replication. Serum is a critical tool for the study of cross-immunity towards naturally occurring SARS-CoV-2 viral variants or model systems such as pseudotyped virus. The availability of reference serum reagents obtained from vaccinated individuals, and produced in volumes large enough to allow distribution, could be used to test for SARS-CoV-2 spike protein binding and neutralization of VOC. This would allow rapid, in vitro characterization of the activity of antibodies elicited by different vaccines against emerging VOC. Further, these can serve as a general reference standard to permit comparison of results and enhance interpretation of study outcomes generated via neutralization and/or spike protein binding antibody assays used by different laboratories across the globe.

for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.24.22269773 doi: medRxiv preprint 6 Here, we report the generation of pooled, large volume reference sera reagents 

Following written informed consent, 68 individuals participated in the study. The study was approved by the University of Iowa Institutional Review Board (IRB, Committee A). Vaccinated subjects with no history of SARS-CoV-2 infection who lacked detectable antibodies to SARS-CoV-2 nucleocapsid but had antibodies to SARS-CoV-2 spike protein were recruited for a study of T cell responses to SARS-CoV-2. A medical history, whole blood, and peripheral blood mononuclear cells were obtained and processed as described (9) . Volunteers who expressed interest were evaluated for blood donation at the Impact Life Blood Services (Coralville, IA). Following a second, written informed consent process, each eligible donor donated one unit (~ 500 mL) of whole blood, which for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.24.22269773 doi: medRxiv preprint 7 was collected into a "dry" bag (without anticoagulant). Each unit was allowed to clot at room temperature for > 4 hours, following which serum was recovered into a separate bag without anticoagulant. Each serum product was frozen at < -20 o C, and units from each vaccine recipient group were shipped together overnight to BEI Resources on frozen packs. Upon receipt, sera remained partially frozen. The sera were allowed to thaw before being pooled and stored in 1 mL (or 25 mL) labeled tubes. Pooled serum aliquots were frozen and stored at -20 o C for subsequent distribution.

Samples from each study volunteer and each pooled serum preparation were evaluated for spike antibody using the LIASON® SARS-CoV-2 S1/S2 IgG assays (Roche The SARS-CoV-2 spike protein receptor binding domain (RBD) contains a receptor binding motif that interacts with angiotensin-converting enzyme 2 (ACE-2) on the cell surface (13) . Antibodies that block cell RBD binding to ACE-2 correlate with neutralizing antibodies (14) . Serum inhibition of RBD binding to ACE-2 was measured using a SARS-CoV-2 spike RBD-ACE2 blocking antibody detection ELISA kit (Cell Signaling Technology, Danvars, MA) as recommended by the manufacturer.

for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Sixty-eight subjects were evaluated at the Iowa City VA or the University of Iowa.

All volunteers were healthy, between 18 and 65 years of age, 43 (63%) were female, 24 male, and 1 was female transgender. The average age of women was 42, and 49 among men. Consistent with local demographics, 2 subjects were African American, 4 were Asian/Pacific Islander, and the remaining 62 were Caucasian, four of whom were Latino. Thirty-five subjects were excluded from participation in the large volume serum donation study for the following reasons: 18 were not interested in blood donation, 2 had baseline spike and nucleocapsid antibodies detected indicating recent infection, 2 had not received COVID-19 vaccines, 2 were excluded due to failure to meet blood donation screening requirements, 1 was unable to complete donation, and 10 were excluded due to low SARS-CoV-2 spike antibody levels (< 160 WHO IU/mL). The remaining 23 subjects This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 ). This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2 ), which likely reflects the significantly longer time period between final vaccine receipt and serum collection. Nucleoprotein-specific antibodies were not detected in any of the serum pools. Inhibition of RBD binding to ACE-2 reflected total spike antibody concentration ( Table 2) .

for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. The SARS-CoV-2 spike protein coding sequence for all four vaccines involved in this study are derived from the same ancestral virus (Wuhan-Hu-1 SARS-CoV-2) with minor differences employed in cloning (reviewed in (15) ). Specifically, all four vaccines contain 2 mutations that prevent the conformational change of the more immunogenic pre-fusion spike protein structure into the post-fusion form. Ad26.COV2.S also contains two mutations at the S1/S2 furin cleavage site, which further stabilizes the S protein in the pre-fusion state. The S protein in NVX-CoV2373 has all of the Ad26.COV2.S changes in addition to a deletion in the furin cleavage site. Further, NVX-CoV2373 trimeric (and multi-trimeric) proteins are expressed and purified before formulation as a nanoparticle, for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.24.22269773 doi: medRxiv preprint 12 which includes a saponin-based adjuvant (Matrix-M TM ) (15) . Due to the high degree of similarity in the spike protein across all four vaccines, differences in antibody responses presumably relate to either host genetic variation, approximate level of vaccine induced immunity/level of wanning immunity post vaccination, and/or differences in vaccine platform (16) . Thus, examination of SARS-CoV-2 vaccine-induced antibody binding to their cognate spike protein or neutralization of the Wuhan-Hu-1 strain provides avenues to evaluate different vaccine platforms. In addition, examination of vaccine-specific antibodies binding to emerging VOC spike proteins and the ability of these antibodies to neutralize VOC, allows for an in vitro surrogate to aid in predicting vaccine effectiveness Another important aspect of these reference reagents is to enhance the ability to compare results generated by different antibody binding, blocking, or neutralization assays across laboratories around the globe. A plethora of SARS-CoV-2 antibody methods have been developed for diagnostic and research purposes that utilize different platforms (ELISA, lateral flow immunoassays, chemiluminescent immunoassays, SARS-CoV-2 neutralization assays, spike protein pseudotyped neutralization assays, spike protein binding to ACE-2 inhibition, etc.) (17) , and it is recognized that results obtained with one assay may vary considerably from that obtained by other laboratories, even when using the same methodology (the so-called reproducibility crisis) (18) . There is hope that by making reference serum controls freely available, an improved understanding of the magnitude of the binding or neutralization measured will be gained, and improved harmonization of results between laboratories will emanate.

We foresee, on behalf of the ACTIV TRACE working group, the creation of additional pooled serum reference reagents. These reagents may include samples for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.24.22269773 doi: medRxiv preprint 13 collected from other vaccination regimens (e.g. subjects who have received vaccine booster doses), or from post-infection convalescent serum with or without vaccination. As new reagents are made available, procedures, protocols, and characterizations will be made available. As a fundamental objective of the ACTIV TRACE initiative, we anticipate widespread distribution of the reagents described in this manuscript via BEI Resources (https://www.beiresources.org/Home.aspx). As reagent-related data are generated, they will be curated, summarized, and shared on the NCATS OpenData Portal (8), thus allowing for the comparison of assays across laboratories and informing on the reproducibility of the global research response to variants of SARS-CoV-2. Development and distribution of these reagents for investigative use against emerging SARS-CoV-2 variants is a driving factor for the ACTIV TRACE working group, as is the timely and open sharing of reagents, protocols, and data to further our understanding and to direct our therapeutic approaches against SARS-CoV-2 VOC as a scientific community. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.24.22269773 doi: medRxiv preprint

Virus evolution

Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing

Quasispecies and virus

It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern

Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic

SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities

An OpenData portal to share COVID-19 drug repurposing data in real time

Human pegivirus RNA is found in multiple blood mononuclear cells in vivo and serum-derived viral RNA-containing particles are infectious in vitro

Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients

It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Head-to-Head Comparison of Two SARS-CoV-2 Serology Assays

Is WHO international standard for anti-SARS-CoV-2 immunoglobulin clinically useful? medRxiv

T-cell expression of angiotensin-converting enzyme 2 and binding of severe acute respiratory coronavirus 2

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron 2 after breakthrough infection by other variants medRxiv

Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Testing: Important but Imperfect

Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery

It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

The authors declare no competing interest.